PIK3CA and neoplasm: Since metastasized MCC is a very aggressive tumor with poor prognosis and very limited therapeutic options, the presented observations are opening the avenue for targeting the activated PI3K/AKT pathway as an interesting new option for patients suffering from advanced MCC.